PfizerLong
PFIZER BULLISH VISION
By waves of eliot we have corrective wave # 2 finished at 50 of fibo, with wave # 3 in process.
Possible rounded soil formation in weekly chart.
In daily charts we see an inverted hch (healthy) formed on the 50 weekly fibo, which would activate after breaking the 40usd (previously it already exceeded this maximum, which indicates weakness of the level).
In H1 charts, we see how the price wants to form a possible double bottom, which if it activates and meets its projection at 39.50usd, it would be activating the hch.
Pfizer is one of the companies with the best market capitalization, with more than 200 billion dollars, it ranks 3rd among the best valued pharmaceutical companies in the world, above industries such as Bayer, Sanofi and Novartis. In addition to being the largest drug store in the United States.
In conclusion, we expect a breakout of 40usd per share to go long on this asset.
To keep in mind, they can take profit at 42.50 which is consistent with the 78.6 level of the last strong bearish momentum.
Possible rounded soil formation in weekly chart.
In daily charts we see an inverted hch (healthy) formed on the 50 weekly fibo, which would activate after breaking the 40usd (previously it already exceeded this maximum, which indicates weakness of the level).
In H1 charts, we see how the price wants to form a possible double bottom, which if it activates and meets its projection at 39.50usd, it would be activating the hch.
Pfizer is one of the companies with the best market capitalization, with more than 200 billion dollars, it ranks 3rd among the best valued pharmaceutical companies in the world, above industries such as Bayer, Sanofi and Novartis. In addition to being the largest drug store in the United States.
In conclusion, we expect a breakout of 40usd per share to go long on this asset.
To keep in mind, they can take profit at 42.50 which is consistent with the 78.6 level of the last strong bearish momentum.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.